Associated Papers
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
40829168 (PubMed )
Supplement: BLOOD_BLD-2024-027692-mmc5.xlsx › Sheet_1
Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing.
Ambayya A et al.
Cancers, 2023
36900179 (PubMed )
Supplement: cancers-15-01386-s001.zip › Supplementary_File_S2.xlsx › Table_S7.Summary_of_variants
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ et al.
Cell Research, 2021
32719455 (PubMed )
Supplement: 41422_2020_375_MOESM12_ESM.xlsx › Sheet1
Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia.
Nishii R et al.
Blood, 2021
Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms.
Park J et al.
Molecular Diagnosis & Therapy, 2020
Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW et al.
Plos One, 2019
31747416 (PubMed )
Supplement: pone.0224227.s002.xlsx › SNV
Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.
Moriyama T et al.
The Lancet. Oncology, 2015
26522332 (PubMed )
Supplement: NIHMS737731-supplement-1.pdf
Mutational analysis of primary central nervous system lymphoma.
Bruno A et al.
Oncotarget, 2014
24970810 (PubMed )
Supplement: oncotarget-05-5065-s001.xls › Table_S2
Select a paper to view details